Matthew J LaMarche

This inventor holds 30 USPTO granted patents and 8 published patent applications and 3 EPO patents. Top assignees: Novartis Ag, University of Pennsylvania, Millennium Pharmaceuticals Limited. Active years: 2001-2025.

USPTO Granted Patents = 30 (Patent Applications = 8)

% Patents Active = 73.3

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 6.3

ph-index = 6

Forward Citations = 100(Granted Patents)

Location History:

Philadelphia, PA (US) (2001 - 2005)
Reading, MA (US) (2005 - 2024)

Company Filing History:

University of Pennsylvania

patents

2 out of 854

Millennium Pharmaceuticals Limited

patents

4. 1 out of 4,186

Abbott Laboratories Corporation

patents

5. 1 out of 3,068

The General Hospital Corporation

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

N-Azaspirocycloalkane Compounds

SHP2 Inhibitors

Pharmaceutical Combinations

Aminothiazoles

Macrocycles

Bicyclic Compounds

Kinase Inhibitory Activity

Synthetic Techniques

Polyhydroxy Dienyl Lactones

Discodermolide Mimics

Melanin Concentrating Hormone Antagonists

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209098 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2025-01-28),

2. 12053470 - Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor (2024-08-06),

3. 11952386 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2024-04-09),

4. 11905283 - Compounds and compositions for inhibiting the activity of SHP2 (2024-02-20),

5. 11401259 - 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2022-08-02),

6. 10975080 - Compounds and compositions for inhibiting the activity of SHP2 (2021-04-13),

7. 10968235 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2021-04-06),

8. 10934285 - Compounds and compositions for inhibiting the activity of SHP2 (2021-03-02),

9. 10774065 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2020-09-15),

10. 10336774 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2019-07-02),

11. 10308660 - Compounds and compositions for inhibiting the activity of SHP2 (2019-06-04),

12. 10301278 - 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 (2019-05-28),

13. 10287266 - Compounds and compositions for inhibiting the activity of SHP2 (2019-05-14),

14. 10130629 - Pharmaceutical combinations (2018-11-20),

15. 10093646 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2018-10-09),

Title: The Inventor Matthew J LaMarche

Introduction: Matthew J LaMarche is a talented inventor based in Reading, MA (US) known for his innovative contributions in various fields.

Latest Patents: Matthew J LaMarche holds several patents in the areas of technology and engineering, showcasing his dedication to pushing the boundaries of innovation.

Career Highlights: Throughout his career, Matthew J LaMarche has demonstrated a keen ability to transform ideas into practical solutions, earning him recognition as a forward-thinker in the industry.

Collaborations: Matthew J LaMarche has collaborated with leading experts and organizations to further his inventions, highlighting his commitment to teamwork and shared success.

Conclusion: Matthew J LaMarche's passion for innovation and his impressive track record make him a standout figure in the world of inventors, with a promising future ahead.